Language:

Endometrial cancer

The Lancet (British edition), 2022-04, Vol.399 (10333), p.1412-1428 [Peer Reviewed Journal]

2022 Elsevier Ltd ;Copyright © 2022 Elsevier Ltd. All rights reserved. ;2022. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)00323-3 ;PMID: 35397864

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Endometrial cancer
Author: Crosbie, Emma J ; Kitson, Sarah J ; McAlpine, Jessica N ; Mukhopadhyay, Asima ; Powell, Melanie E ; Singh, Naveena
Subjects: Abdomen ; Age ; Aging ; Biopsy ; Cancer ; Clinical trials ; Diabetes ; Endometrial cancer ; Endometrium ; Hysterectomy ; Insulin-like growth factors ; Invasiveness ; Low income groups ; Medical screening ; Menstruation ; Molecular biology ; Morbidity ; Mortality ; Obesity ; Pathology ; Polycystic ovary syndrome ; Post-menopause ; Radiation therapy ; Risk ; Risk factors ; Survival ; Ultrasonic imaging ; Womens health
Is Part Of: The Lancet (British edition), 2022-04, Vol.399 (10333), p.1412-1428
Description: Endometrial cancer is the most common gynaecological cancer in high income countries and its incidence is rising globally. Although an ageing population and fewer benign hysterectomies have contributed to this trend, the growing prevalence of obesity is the major underlying cause. Obesity poses challenges for diagnosis and treatment and more research is needed to offer primary prevention to high-risk women and to optimise endometrial cancer survivorship. Early presentation with postmenopausal bleeding ensures most endometrial cancers are cured by hysterectomy but those with advanced disease have a poor prognosis. Minimally invasive surgical staging and sentinel-lymph-node biopsy provides a low morbidity alternative to historical surgical management without compromising oncological outcomes. Adjuvant radiotherapy reduces loco-regional recurrence in intermediate-risk and high-risk cases. Advances in our understanding of the molecular biology of endometrial cancer have paved the way for targeted chemotherapeutic strategies, and clinical trials will establish their benefit in adjuvant, advanced, and recurrent disease settings in the coming years.
Publisher: England: Elsevier Ltd
Language: English
Identifier: ISSN: 0140-6736
EISSN: 1474-547X
DOI: 10.1016/S0140-6736(22)00323-3
PMID: 35397864
Source: ProQuest One Psychology
ProQuest Central

Back to results list

Previous Result 20 Next Go to Next page


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Endometrial cancer

2022 Elsevier Ltd ;Copyright © 2022 Elsevier Ltd. All rights reserved. ;2022. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)00323-3 ;PMID: 35397864

Searching Remote Databases, Please Wait